Greatest International Antiinfective Trial With Avelox

Bayer50,000 enrolled

Overview

The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Study Type

OBSERVATIONAL

Enrollment

50,000

Conditions

Bronchitis, Chronic Bronchial Diseases

Interventions

Moxifloxacin (Avelox, BAY12-8039)DRUG

AECB patients under daily life treatment receiving moxifloxacin according to the local product information.

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin Exclusion Criteria: * Exclusion criteria must be read in conjunction with the local product information

Locations (24)

Unnamed facility

Many Locations, Austria

Unnamed facility

Many Locations, Brazil

Unnamed facility

Many Locations, China

Outcomes

Primary Outcomes

Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice

Time frame: During documentation at baseline and at at least one short-term follow-up visit; at maximum two short-term (within ca. 14 days) and two long-term follow-up visits (after ca. 6 and 12 months).

Secondary Outcomes

Course of symptom relief

Time frame: During documentation of up to two short-term follow-up visits (within ca. 14 days)

Speed of return to normal daily life activities

Time frame: During documentation of the last short-term follow-up visit (after ca. 14 days)

Adverse events collection

Time frame: Throughout the entire study, whenever Adverse Events occur

Evaluation of frequency of new exacerbations

Time frame: During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months)

Progression of chronic respiratory disease

Time frame: During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.